Quantum Leap Healthcare Collaborative and Athenex Announce the Selection of Oral Paclitaxel plus Encequidar in Combination with dostarlimab, an anti-PD-1, in the I-SPY 2 TRIAL targeting Stage 2/3 HER2+ and HER2- Breast Cancers

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing